CymitQuimica logo
BTK

BTK

BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.

Found 145 products of "BTK"

Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
products per page.
  • ARQ 531

    CAS:
    <p>ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.</p>
    Formula:C25H23ClN4O4
    Purity:98.68% - 99.63%
    Color and Shape:Solid
    Molecular weight:478.93
  • AS-1763

    CAS:
    <p>AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.</p>
    Formula:C33H31FN6O3
    Purity:≥95%
    Color and Shape:Solid
    Molecular weight:578.64
  • Orelabrutinib

    CAS:
    <p>Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).</p>
    Formula:C26H25N3O3
    Purity:97.77% - 99.54%
    Color and Shape:Solid
    Molecular weight:427.49
  • Tirabrutinib hydrochloride

    CAS:
    <p>Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.</p>
    Formula:C25H23ClN6O3
    Purity:99.04% - 99.27%
    Color and Shape:Solid
    Molecular weight:490.94
  • Rilzabrutinib

    CAS:
    <p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>
    Formula:C36H40FN9O3
    Purity:98.28% - 99.76%
    Color and Shape:Solid
    Molecular weight:665.76
  • MT-802

    CAS:
    <p>MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).</p>
    Formula:C41H41N9O8
    Purity:95.93% - 97%
    Color and Shape:Solid
    Molecular weight:787.82
  • Btk inhibitor 2

    CAS:
    <p>Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.</p>
    Formula:C24H25N5O3
    Purity:99.94%
    Color and Shape:Solid
    Molecular weight:431.49
  • IBT6A

    CAS:
    <p>IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>
    Formula:C22H22N6O
    Purity:99.8% - 99.88%
    Color and Shape:Solid
    Molecular weight:386.45
  • SJF620 hydrochloride

    CAS:
    <p>SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].</p>
    Formula:C41H45ClN8O7
    Purity:98%
    Color and Shape:Solid
    Molecular weight:797.3
  • FDA-Approved Kinase Inhibitor Library


    <p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>
    Color and Shape:Liquid
  • DD 03-171

    CAS:
    <p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>
    Formula:C55H62N10O8
    Color and Shape:Solid
    Molecular weight:991.163
  • BTK-IN-5

    CAS:
    <p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>
    Formula:C23H32N4O5
    Color and Shape:Solid
    Molecular weight:444.532
  • GBD-9

    CAS:
    <p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>
    Formula:C44H47N9O6
    Purity:98%
    Color and Shape:Solid
    Molecular weight:797.9
  • TLT8


    <p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>
    Color and Shape:Odour Solid
  • NRX-0492

    CAS:
    <p>NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.</p>
    Formula:C43H51N11O6
    Color and Shape:Solid
    Molecular weight:817.94
  • PTD10

    CAS:
    <p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>
    Formula:C49H51N11O8
    Purity:98%
    Color and Shape:Solid
    Molecular weight:922
  • PROTAC BTK Degrader-1

    CAS:
    <p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>
    Formula:C43H43N9O4
    Color and Shape:Solid
    Molecular weight:749.86
  • BTK ligand-14


    <p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>
    Color and Shape:Odour Solid
  • BRK inhibitor P21d hydrochloride

    CAS:
    <p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>
    Formula:C23H23ClFN7O2
    Color and Shape:Solid
    Molecular weight:483.93
  • Tyrosinase-IN-16

    CAS:
    <p>Tyrosinase-IN-16 inhibited tyrosinase.</p>
    Formula:C8H6BrN3S
    Purity:99.57%
    Color and Shape:Solid
    Molecular weight:256.12